Differences

This shows you the differences between two versions of the page.

--- philippe_de_wals [2022/04/21 09:28]
liam [Career and Affiliations]
+++ philippe_de_wals [2022/04/21 10:10] (current)
liam [Research]
@@ Line 43: / Line 43: @@
 ===== Research =====
-De Wals has received research grants and travel reimbursement from [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Novartis]], [[pharmaceutical_companies:Pfizer]], and [[pharmaceutical_companies:Sanofi]]. Additional funding has come from the [[Public Health Agency of Canada]] and the [[Quebec Ministry of Health and Social Services]].((Cléophat, J.-E., Le Meur, J.-B., Proulx, J.-F., & De Wals, P. (2014). //Uptake of pneumococcal vaccines in the Nordic region of Nunavik, province of Quebec, Canada.// Canadian Journal of Public Health, 105(4), e268–e272. https://doi.org/10.17269/cjph.105.4315))
+De Wals has received research grants and travel reimbursement from [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Novartis]], [[pharmaceutical_companies:Pfizer]], and [[pharmaceutical_companies:Sanofi]]. Specifically, he benefited from unrestricted research grants from GlaxoSmithKline, Pfizer, and Sanofi, for whom he has also served as scientific advisor.((De Wals, P. (2019). //Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.// Canadian Journal of Infectious Diseases and Medical Microbiology, 2019, 1–11. https://doi.org/10.1155/2019/8901847)) ((De Wals, P. (2015, October 10). //Economic Analysis of Pneumococcal Vaccination for Elderly Adults in Quebec: Forecasting Invasive Pneumococcal Disease (IPD) Rates of and Serotype Distribution.// Confex; Infectious Diseases Society of America. https://archive.ph/gxSeC))
+Additional funding has come from the [[Public Health Agency of Canada]] and the [[Quebec Ministry of Health and Social Services]].((Cléophat, J.-E., Le Meur, J.-B., Proulx, J.-F., & De Wals, P. (2014). //Uptake of pneumococcal vaccines in the Nordic region of Nunavik, province of Quebec, Canada.// Canadian Journal of Public Health, 105(4), e268–e272. https://doi.org/10.17269/cjph.105.4315))
+In 2021, De Wals participated in the The Pneumococcal Serotype Replacement and Distribution Estimation ([[PSERENADE]]) Project, funded by the [[Bill & Melinda Gates Foundation]] as part of the [[World Health Organization]] [[Pneumococcal Vaccines Technical Coordination Project]].((Deloria Knoll, M., Bennett, J., Garcia Quesada, M., Kagucia, E., Peterson, M., Feikin, D., Cohen, A., Hetrich, M., Yang, Y., Sinkevitch, J., Ampofo, K., Aukes, L., Bacci, S., Bigogo, G., Brandileone, M.-C., Bruce, M., Camilli, R., Castilla, J., Chan, G., & Chanto Chacón, G. (2021). //Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.// Microorganisms, 9(4), 742. https://doi.org/10.3390/microorganisms9040742))